Guided Therapeutics, Inc.
GTHP
$0.29
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 108.53% | -13.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 112.56% | -22.62% | |||
| Operating Income | -84.30% | 22.47% | |||
| Income Before Tax | -89.93% | 34.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -89.93% | 34.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -89.93% | 34.51% | |||
| EBIT | -84.30% | 22.47% | |||
| EBITDA | -84.47% | 22.56% | |||
| EPS Basic | -60.29% | 40.35% | |||
| Normalized Basic EPS | -71.05% | 44.12% | |||
| EPS Diluted | -9.00% | 48.19% | |||
| Normalized Diluted EPS | -71.05% | 44.12% | |||
| Average Basic Shares Outstanding | 15.44% | 10.92% | |||
| Average Diluted Shares Outstanding | 15.44% | 10.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||